250 related articles for article (PubMed ID: 16728568)
1. The emerging roles of DNA methylation in the clinical management of prostate cancer.
Perry AS; Foley R; Woodson K; Lawler M
Endocr Relat Cancer; 2006 Jun; 13(2):357-77. PubMed ID: 16728568
[TBL] [Abstract][Full Text] [Related]
2. Methylated genes as potential biomarkers in prostate cancer.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.
Reibenwein J; Pils D; Horak P; Tomicek B; Goldner G; Worel N; Elandt K; Krainer M
Prostate; 2007 Mar; 67(4):427-32. PubMed ID: 17192910
[TBL] [Abstract][Full Text] [Related]
5. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
6. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
[TBL] [Abstract][Full Text] [Related]
7. Gene promoter methylation and its potential relevance in early prostate cancer diagnosis.
Steiner I; Jung K; Schatz P; Horns T; Wittschieber D; Lein M; Dietel M; Erbersdobler A
Pathobiology; 2010; 77(5):260-6. PubMed ID: 21116117
[TBL] [Abstract][Full Text] [Related]
8. Gene promoter methylation in prostate tumor-associated stromal cells.
Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.
Woodson K; O'Reilly KJ; Hanson JC; Nelson D; Walk EL; Tangrea JA
J Urol; 2008 Feb; 179(2):508-11; discussion 511-2. PubMed ID: 18076912
[TBL] [Abstract][Full Text] [Related]
10. [Detection of DNA hypermethylation as a potential biomarker for prostate cancer].
Tilandyová P; Kajo K; Kliment J; Plank L; Lasabová Z
Klin Onkol; 2010; 23(5):293-9. PubMed ID: 21061679
[TBL] [Abstract][Full Text] [Related]
11. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation.
Henrique R; Jerónimo C
Eur Urol; 2004 Nov; 46(5):660-9; discussion 669. PubMed ID: 15474280
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
Richiardi L; Fiano V; Vizzini L; De Marco L; Delsedime L; Akre O; Tos AG; Merletti F
J Clin Oncol; 2009 Jul; 27(19):3161-8. PubMed ID: 19470943
[TBL] [Abstract][Full Text] [Related]
14. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.
Meiers I; Shanks JH; Bostwick DG
Pathology; 2007 Jun; 39(3):299-304. PubMed ID: 17558856
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
Bernardini S; Miano R; Iori R; Finazzi-Agrò E; Palmieri G; Ballerini S; Angeloni C; Orlandi A; Bellincampi L; Cortese C; Federici G
Clin Chim Acta; 2004 Dec; 350(1-2):181-8. PubMed ID: 15530476
[TBL] [Abstract][Full Text] [Related]
16. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
[TBL] [Abstract][Full Text] [Related]
17. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.
Cairns P; Esteller M; Herman JG; Schoenberg M; Jeronimo C; Sanchez-Cespedes M; Chow NH; Grasso M; Wu L; Westra WB; Sidransky D
Clin Cancer Res; 2001 Sep; 7(9):2727-30. PubMed ID: 11555585
[TBL] [Abstract][Full Text] [Related]
18. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
